BioLife Solutions director disposes of 13,871 shares
BioLife Solutions director Catherine Coste sold 13,871 shares on October 6, 2026, as part of a merger with Repligen. Under the merger terms, each BioLife share converted to $11.25 in cash and 0.1442 Repligen shares, per the merger agreement.
How this was made
The 30-second read
Why it matters
The insider disposition is the first public report of the director's sale, providing new information for traders.
Market read
Primary disclosure of insider sale; modest trading relevance.
What to watch
Potential tax planning or diversification needs of the director.
Background
BioLife Solutions is completing a merger with Repligen, converting shares into cash and Repligen stock.
Ticker impact
Director Catherine Coste disposed of 13,871 shares in a Form 4 filing related to the merger.
likely downward pressure as market prices in the insider disposition
The filing is a primary disclosure of a director selling a sizable block; such sales often trigger short-term sell pressure.
Market effects
Minimal impact on the broader biotech sector; the news is company‑specific.
Limited to U.S. markets where BLFS trades.
Low global relevance.
Counterpoint
The sale could be a routine liquidity move unrelated to fundamentals.
Key entities
- companyBioLife Solutions
Biotech firm undergoing merger with Repligen.
- personCatherine Coste
Director of BioLife Solutions who sold shares.
